Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

1
Player Avatar 1badbeerad (44.25) Submitted: 6/4/2013 1:05:57 PM : Outperform Start Price: $59.22 CELG Score: +33.40

whatta pipeline

Featured Broker Partners


Advertisement